

## Laurus Labs receives USFDA approval for Metformin Hydrochloride Tablets USP

Hyderabad, August 29, 2018, Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010)

Laurus Labs is pleased to announce that the Company has received an approval from United States Food and Drug Administration (US FDA) for **Metformin Hydrochloride Tablets USP 500mg, 850mg and 1000mg** which are used for treatment of diabetes.

Metformin Hydrochloride Tablets USP 500mg, 850mg, and 1000mg are therapeutically equivalent to Glucophage Tablets 500mg, 850mg, and 1000 mg of Bristol-Myers Squibb Company.

The Product and API will be commercialized from Company's Unit 2 located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.

### **About Laurus Labs Limited:**

Laurus is a leading research and development driven pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus also manufactures APIs in Oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area. Initiatives are in place to develop a Finished Dosages Forms capability on the back of existing strengths in APIs. The Company is also driving growth opportunities in the Synthesis and Ingredients businesses. Corporate Identification **No: L24239AP2005PLC047518**.

For more information about us, please visit <http://www.lauruslabs.com> or Contact particulars:

**Pavan Kumar N**  
**Laurus Labs Ltd.**

**Tel:** +91 40 3980 4380/ 733 735 3848  
**Email:** [mediarelations@lauruslabs.com](mailto:mediarelations@lauruslabs.com)

### **DISCLAIMER:**

Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

